Lykos therapeutics

​Lykos Therapeutics, formerly known as MAPS Public Benefit Corporation (MAPS PBC), is a public benefit corporation focused on developing MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Established in 2014 as a subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), the company rebranded to Lykos Therapeutics in January 2024 to reflect its evolving mission. Lykos Therapeutics primarily serves individuals suffering from PTSD, aiming to provide innovative, evidence-based therapeutic options to improve mental health outcomes